Pharmaceutical companies have been positive in consistency evaluation, and a large number of drugs have been evaluated within a week
Time of Update: 2022-10-01
Chinese medicine cefotaxime sodium review Chinese medicine cefotaxime sodium review China Pharmaceutical announced on September 23 that GM Sanyo, a wholly-owned subsidiary of the company, received two copies of the "Notice of Approval of Drug Supplement Application for Drug Supplementation" issued by the State Food and Drug Administration for injection of cefotaxime sodium, which passed the consistency evaluation of generic drug quality and efficacy.
The amazing health benefits of cold water therapy
Time of Update: 2022-05-26
Can cold therapy help with weight loss?Cold increases your metabolism and activates thermogenesis, in which brown fat burns calories to produce heat .
Chinese PD-(L)1 "roll" to the United States
Time of Update: 2022-02-23
2022 FDA Approval Plan for PD-(L)1 Monoclonal AntibodySource: evaluatePD-(L)1 is "rolling" all over the worldPD-(L)1 is "rolling" all over the worldAccording to Yaozhi data, as of January 6, 2022, the total number of global clinical trials of PD-1 target drugs has reached 3471, of which China (CDE registration) is 675, accounting for about 19.
The price of this new AD drug will be reduced by 50% from January next year
Time of Update: 2021-12-24
It should be noted that, unlike the increasing number of patients, in the medical industry, the development of new drugs for Alzheimer’s disease is very Mount Everest, which is difficult to climb, has a very high risk and failure rate; this has also led to the fact that since the discovery of Alzheimer’s disease for more than 100 years, there are still few drugs used for clinical treatment in the world, and they are expensive.
The fifth batch of national drug procurement will open bids, involving anti-cancer drugs, antihypertensive drugs, etc
Time of Update: 2021-06-10
(China News Network)A few days ago, the National Organization for Pharmaceutical Joint Procurement Office released the fifth batch of national drug procurement product catalogs, and determined 62 varieties to participate in this procurement, including anticancer drugs, antibiotics, hypertension-related drugs, ophthalmology-related drugs, and psychotropic drugs, etc.
From 2021, Shanghai can allow medical device wholesale enterprises "one certificate multi-site
Time of Update: 2021-01-14
"Notice" clearly, in order to improve the relevance and effectiveness of supervision, urge medical device wholesale enterprises to standardize the establishment of cross-regional business premises, further implement the responsibility of regional supervision, after research and decision in Pudong New Area, Hongkou District, Baoshan District, Songjiang District, Jiading District within the five jurisdictions to carry out medical device wholesale enterprises "one certificate multi-site" supervision pilot.
7 injections have been rated 3 times! 5 billion varieties to pass through again; Yangzijiang, Xiansheng, Koren
Time of Update: 2020-12-30
Libawelin tablets domestic market approval has 163, manufacturers 126, only 3 enterprises declared consistency evaluation was accepted, this week, Guangdong South China Pharmaceutical Industry, Jiangsu Morning Brand Pharmaceutical Industry has passed the variety consistency evaluation.
Breakthrough drug for chronic graft anti-host disease (cGVHD)! ROCK2 inhibitor belumosudil U.S. entry review: total mitigation rate > 70
Time of Update: 2020-12-20
December 04, 2020 // -- Kadmon Holdings recently announced that the U.S. Food and Drug Administration (FDA) has accepted a new drug application (NDA) from Belumosudil (KD025), an oral selective Rho-associated coil protein kinase 2 (ROCK2) inhibitor used to treat patients with chronic graft anti-host disease (cGVHD).
Hereditary angioedema (HAE) the first oral therapy! FDA approves plasma kinetic peptide release enzyme inhibitor Orladeyo (berotralstat
Time of Update: 2020-12-19
it's worth noting that Orladeyo is the first targeted oral therapy approved to prevent HAE seizures, and its approval will make significant progress in the treatment of HAE patients and help reduce the burden of treatment for patients.
Wenda Pharmaceutical BET inhibitors were approved clinically
Time of Update: 2020-10-15
According to the latest data on the website of the Drug Review Center (CDE) of the State Drug Administration of China, NHWD-870 HCl tablets, a class 1 innovative drug jointly declared by Wenda Pharmaceuticals and Hengya Pharmaceuticals, have obtained two clinical tacit licenses in China to develop treatments for advanced recurrence of non-Hodgkin's lymphoma, skin/mucosal melanoma, non-small cell lung cancer and small cell lung cancer.
What specifics should be included in the end of clinical trials for COVID-19 therapeutic drugs
Time of Update: 2020-08-25
At a recent remote meeting of the International Union of Drug Regulators, representatives of ICMRA member agencies considered potential endpoints and agreed on acceptable end points with a view to facilitating rapid and consistent clinical trials of COVID-19 drugs.
Sixty percent of the respondents approveofd for nutritious health food? They prefer simple, direct effects to propaganda
Time of Update: 2020-08-13
here to choose tonic health and nutritional supplements under the two categories, Tmall sales of the top 1000 goods as a reference, to study consumer preferences for health care products.
How much room is there for price reduction in centralized procurement? Great price comparison of generic drugs between China and India
Time of Update: 2020-05-31
In fact, the results of the purchase of the "4 plus 7" expansion band in September this year, compared with the 2018 minimum purchase price in the Alliance region, the proposed winning price decreased
New requirements for related review and approval of the original auxiliary package, implemented on August 15
Time of Update: 2019-07-17
In order to implement the opinions of the general office of the CPC Central Committee and the general office of the State Council on deepening the reform of the review and approval system and encourag
Li Yan, Qilu Pharmaceutical Co., Ltd.: bringing the evaluation of clinical research development ability into the level evaluation of medical institutions
Time of Update: 2019-03-05
The second session of the 13th National People's Congress will be held in Beijing on March 5 Li Yan, deputy to the National People's Congress and President of Qilu Pharmaceutical Group, arrived in Bei